<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008137</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-PanFlu-4002</org_study_id>
    <nct_id>NCT01008137</nct_id>
  </id_info>
  <brief_title>Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults</brief_title>
  <official_title>Cell-mediated Immunity Study of H1N1 Influenza A Vaccine With Trivalent Inactivated Influenza Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <brief_summary>
    <textblock>
      A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years)&#xD;
      to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's&#xD;
      H1N1 influenza A Vaccine (PANFLU.1) with Trivalent Inactivated Influenza Vaccine (ANFLU).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in adults</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in adults</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: Day 0-PANFLU.1; Day 21-ANFLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Day 0-ANFLU; Day 21-PANFLU.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Day 0-PANFLU.1+ANFLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H1N1 influenza A Vaccine (PANFLU.1)</intervention_name>
    <description>H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)</description>
    <arm_group_label>Group 1: Day 0-PANFLU.1; Day 21-ANFLU</arm_group_label>
    <arm_group_label>Group 2: Day 0-ANFLU; Day 21-PANFLU.1</arm_group_label>
    <arm_group_label>Group 3: Day 0-PANFLU.1+ANFLU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent Inactivated Influenza Vaccine (ANFLU)</intervention_name>
    <description>Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)</description>
    <arm_group_label>Group 1: Day 0-PANFLU.1; Day 21-ANFLU</arm_group_label>
    <arm_group_label>Group 2: Day 0-ANFLU; Day 21-PANFLU.1</arm_group_label>
    <arm_group_label>Group 3: Day 0-PANFLU.1+ANFLU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female aged between 18 and 60&#xD;
&#xD;
          2. Be able to show legal identity card for the sake of recruitment&#xD;
&#xD;
          3. Volunteers are able to understand and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cases, cured cases and close contact of influenza A (H1N1) virus&#xD;
&#xD;
          2. History of H1N1 vaccine or seasonal influenza vaccine administration&#xD;
&#xD;
          3. Women of pregnancy, lactation or about to be pregnant in 60 days&#xD;
&#xD;
          4. Subject that has a medical history of any of the following: allergic history, or&#xD;
             allergic to any ingredient of vaccine, such as egg, egg protein, etc&#xD;
&#xD;
          5. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory&#xD;
             difficulty, angioedema, or abdominal pain&#xD;
&#xD;
          6. Autoimmune disease or immunodeficiency&#xD;
&#xD;
          7. Asthma that is unstable or required emergent care, hospitalization or intubation&#xD;
             during the past two years or that required the use of oral or intravenous&#xD;
             corticosteroids&#xD;
&#xD;
          8. Diabetes mellitus (type I or II), with the exception of gestational diabetes&#xD;
&#xD;
          9. History of thyroidectomy or thyroid disease that required medication within the past&#xD;
             12 months&#xD;
&#xD;
         10. Serious angioedema episodes within the previous 3 years or requiring medication in the&#xD;
             previous two years&#xD;
&#xD;
         11. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with IM injections or blood draws&#xD;
&#xD;
         12. Active malignancy or treated malignancy for which there is not reasonable assurance of&#xD;
             sustained cure or malignancy that is likely to recur during the period of study&#xD;
&#xD;
         13. Seizure disorder other than:&#xD;
&#xD;
               -  Febrile seizures under the age of two years old&#xD;
&#xD;
               -  Seizures secondary to alcohol withdrawal more than 3 years ago, or&#xD;
&#xD;
               -  A singular seizure not requiring treatment within the last 3 years&#xD;
&#xD;
         14. Asplenia, functional asplenia or any condition resulting in the absence or removal o&#xD;
             the spleen&#xD;
&#xD;
         15. Guillain-Barre Syndrome&#xD;
&#xD;
         16. Any history of immunosuppressive medications or cytotoxic medications or inhaled&#xD;
             corticosteroids within the past six months (with the exception of corticosteroid nasal&#xD;
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated&#xD;
             dermatitis)&#xD;
&#xD;
         17. History of any blood products within 3 months before the dosing&#xD;
&#xD;
         18. Administration of any other investigational research agents within 30 days before the&#xD;
             dosing&#xD;
&#xD;
         19. Administration of any live attenuated vaccine within 30 days before the dosing&#xD;
&#xD;
         20. Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or&#xD;
             allergy treatment with antigen injections, within 14 days before the dosing&#xD;
&#xD;
         21. Be receiving anti-TB prophylaxis or therapy currently&#xD;
&#xD;
         22. Axillary temperature &gt; 37.0 centigrade at the time of dosing&#xD;
&#xD;
         23. Psychiatric condition that precludes compliance with the protocol:&#xD;
&#xD;
               -  Past or present psychoses&#xD;
&#xD;
               -  Past or present bipolar disorder requiring therapy that has not been well&#xD;
                  controlled on medication for the past two years&#xD;
&#xD;
               -  Disorder requiring lithium&#xD;
&#xD;
               -  Suicidal ideation occurring within five years prior to enrollment&#xD;
&#xD;
         24. Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer's ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Centers for Diseases Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

